Hospital

Providers must carefully prescribe, monitor, and adjust renally relevant drug lists in patients with chronic kidney disease to prevent progression.

Patients with acute migraines should assess their condition before starting a treatment regimen.

Pharmacists play an important role in providing education and support with adherence to PrEP in populations with a high risk for HIV infection.

Intensive health behavior and lifestyle treatment is the most effective behavioral treatment for childhood obesity.

Moderator Curtis E. Haas, PharmD, FCCP; Deborah Simonson, PharmD; Andrew J. Donnelly, PharmD, MBA, FASHP; Noelle Chapman, PharmD, MBA, BCPS, FASHP; Todd Nesbit, PharmD, MBA, FASHP, discuss current challenges facing health-system pharmacies as well as potential solutions in areas such as staffing and financial stress.

Lisocabtagene maraleucel is a CD19-directed CAR T-cell therapy with a 4-1BB costimulatory domain, which enhances the expansion and persistence of the CAR T cells.

The updated label now includes patients with cold agglutinin disease with or without a history of transfusions.

A community-based multidisciplinary team can have a significant impact addressing health disparities and diabetes management.

Economic food insecurity, associated with cardiovascular mortality, disproportionately impacts Black communities.

The efficacy and adverse effects associated with COVID-19 vaccines is a leading cause of hesitancy in parents, according to a new study.

The test, called VirSNiP SARS-CoV-2 Spike F486P, is for research use only and specifically targets the unique mutation F486P found within the XBB.1.5 Omicron sub-variant.

Spinal cord stimulation has been used for 50 years to effectively manage chronic pain without opioids.

Variety of interventions improves morbidity, mortality, associated costs for patients with chronic obstructive pulmonary disorder.

Promising results for lecanemab's efficacy in patients with mild cognitive impairment or mild dementia associated with Alzheimer disease were accompanied by reports of adverse effects associated with treatment.

Mortality was highest among Asian, Black, and Hispanic populations, American Heart Association’s 2023 Statistical Update shows.

By setting a standard for prescriptions that improves member access, outcomes, and experience, we will establish a path forward for every facet of health care.

Increasing efforts have focused on treating COVID-19 among patients in rural areas, who can take advantage of traditional medicines.

Patients who received first-line ICI showed a significant improvement in progression-free survival (PFS) and overall survival (OS) compared to chemotherapy treatment.

Academic, community, first responder, government, and medical leaders call for better options to save lives.

Pembrolizumab approved as adjuvant treatment following surgical resection and platinum-based chemotherapy for patients with stage IB, II, or IIIA non-small cell lung cancer.

When replaced with just 6 to 7 minutes daily of light-intensity exercise or sedentary behavior, data show poorer cognitive performance.

Findings suggest cancer may have overtaken cardiovascular disease as a leading cause of death in individuals with type 2 diabetes.

Relatively higher suicide risks were observed for cancer types with a poor prognosis and high symptom burden in the first 2 years after diagnosis.

Most individuals who used cannabis to manage their chronic pain reported using it in place of other pain medications, including opioids.

Chronochemotherapy aims to time drug delivery when the body is the least vulnerable to harmful effects, while the cancer cells are the most vulnerable.

Respiratory syntactical virus burdens quality of life and can lead to long-term health outcomes.

At leukapheresis, a low frequency of differentiated CD3+CD27-CD28--T cells can indicate favorable response to CAR T-cell therapy.

Pharmacist involvement in identifying causes, therapy approaches is essential, as BCC can result from prior radiation therapy.

Zolbetuximab treatment reduced risk of death by 25% compared to placebo.

Based on study findings, Moderna plans to submit for regulatory approval in the first half of 2023 for mRNA-1345, a novel vaccine for respiratory syncytial virus.